Doximity Inc (DOCS)
Healthcare
Health Information Services
20.90 $
Closing price · As of: 31. Jul 2026
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Doximity Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Basics
Market Cap
The value of the entire company on the market: share price times total shares outstanding.
3.8$B
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
132Mio.
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
97.5%
Beta
Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.
1.3
Performance
Perf. 1M
Price performance over the last month.
-2.30%
Perf. 3M
Price performance over the last 3 months.
-13.10%
Perf. 6M
Price performance over the last 6 months.
-53.00%
YTD Performance (%)
Price performance since the start of the year (Year to Date).
-53.70%
52-Week-High Distance
How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.
-74.1%
Valuation
P/E
Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
–
Forward P/E
P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.
15.3
PEG
P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
0.6
P/B
Price-to-book ratio: market value relative to book equity.
–
P/S
Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.
5.9
EV/EBITDA
Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.
14.2
Price/FCF
Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.
12.0
Profitability
Gross Margin
Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.
89.1%
EBIT Margin
EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.
21.6%
Net Margin
Net margin: what's left of sales as profit after ALL costs, interest, and taxes.
30.4%
Return on Equity
Return on equity: how much profit does the company generate per year on shareholders' equity?
19.3%
Return on Assets
Return on assets: how much profit the company generates from its total assets (equity and debt combined).
11.6%
Balance Sheet & Safety
Equity Ratio
Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.
84.6%
Debt/Equity
Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.
–
fortress balance sheet
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
14.98
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
6 out of 9
Growth
Sales Growth Last Quarter
Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).
5.10%
EPS Growth Last Quarter
Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).
-69.00%
Sales Growth (Year)
Sales growth in the last fiscal year versus the year before.
13.05%
Forward Sales Growth
Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.
6.34%
Forward EPS Growth
Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.
11.40%
Quality & Screener
Stage
Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.
4
RS Rating
Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.
4
EPS Rating
Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.
9
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
6 out of 9
Fundamental Rating
Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below.
C (54 out of 100)
fortress balance sheet
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
14.98
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.37 | 55.40 | 169 | 24.60 | 44.60 | 65 | 63 |
| 2025: Q1 | 0.31 | 52.30 | 138 | 17.10 | 45.20 | 99 | 97 |
| 2025: Q2 | 0.27 | 27.60 | 146 | 15.20 | 36.50 | 62 | 60 |
| 2025: Q3 | 0.31 | 40.30 | 169 | 23.20 | 36.80 | 94 | 92 |
| 2025: Q4 | 0.31 | -16.90 | 185 | 9.80 | 33.30 | 61 | 59 |
| 2026: Q1 | 0.10 | -68.10 | 145 | 5.10 | 13.10 | 110 | 107 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Doximity, Inc. betreibt eine digitale Plattform für medizinische Fachkräfte in den USA.
| Employees | 880 |
|---|---|
| Headquarters | San Francisco, CA |
| Website | doximity.com |
| IPO Date | 24. Jun 2021 |
| Next Earnings | 6. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jeffrey A. Tangney | Co-Founder, CEO & Chairperson | 1973 |
| Steven L. Zatz M.D. | President | 1957 |
| Matthew Sonefeldt | CFO & Principal Financial Officer | 1980 |
| Siddharth Sitaram | Chief Accounting Officer | – |
| Jey Balachandran | Chief Technology Officer | – |
| Perry Scott Gold | Head of Investor Relations | – |
| John Vaughan | General Counsel, Corporate Secretary & Chief Compliance Officer | – |
| Bruno Miranda | Senior Vice President of Engineering | – |
| Joel Davis | Senior Vice President of Product | – |
| Ben Greenberg | Senior VP & GM Commercial Products | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. Jul 2026 | Sitaram Siddharth | Chief Accounting Officer | Sell | 1,732 | 22.02 | 38,139 |
| 15. Jul 2026 | Sitaram Siddharth | Chief Accounting Officer | Other | 4,800 | – | – |
| 13. Jul 2026 | Benjamin Regina M. | Director | Other | 21,314 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.